FMS‐like tyrosine kinase 3 ( FLT3 ) amplification in patients with metastatic colorectal cancer
Autor: | Hisato Kawakami, Hiroko Hasegawa, Ken Kato, Hiroki Hara, Tomohiro Nishina, Naoki Izawa, Tadamichi Denda, Yoshinori Kagawa, Akihito Tsuji, Yoshiaki Nakamura, Izumi Miki, Toshikazu Moriwaki, Yasutoshi Sakamoto, Kentaro Yamazaki, Eiji Oki, Takeshi Kato, Tomohiro Nishida, Satoshi Yuki, Hiromichi Ebi, Wataru Okamoto, Satoshi Fujii, Toshiki Masuishi, Manabu Shiozawa, Takayuki Yoshino, Hiroya Taniguchi, Taito Esaki |
---|---|
Rok vydání: | 2020 |
Předmět: |
Male
0301 basic medicine Oncology Cancer Research Pyridines Colorectal cancer next‐generation sequencing chemistry.chemical_compound fluids and secretions 0302 clinical medicine hemic and lymphatic diseases Aged 80 and over FLT3 amplification hemic and immune systems General Medicine Middle Aged Treatment efficacy Haematopoiesis Treatment Outcome 030220 oncology & carcinogenesis embryonic structures Original Article Female Colorectal Neoplasms Adult medicine.medical_specialty colorectal cancer Antineoplastic Agents Adenocarcinoma Young Adult 03 medical and health sciences Clinical Research Cancer genome Internal medicine Regorafenib medicine Humans In patient Gene Aged Retrospective Studies business.industry Phenylurea Compounds copy number status Gene Amplification medicine.disease 030104 developmental biology fms-Like Tyrosine Kinase 3 chemistry Fms-Like Tyrosine Kinase 3 prognosis business |
Zdroj: | Cancer Science |
ISSN: | 1349-7006 1347-9032 |
Popis: | FMS‐like tyrosine kinase 3 (FLT3) plays a key role in hematopoiesis. However, the oncogenic role of FLT3 amplification in patients with metastatic colorectal cancer (mCRC) remains unclear. Here, we aimed to evaluate the characteristics, prognosis, and treatment efficacy of an FLT3 inhibitor (regorafenib) in patients with mCRC with FLT3 amplifications. Tumor tissue samples from 2329 patients were sequenced using NGS in the Nationwide Cancer Genome Screening Project in Japan. The effects of clinicopathological features, co‐altered genes, prognosis, and efficacy of regorafenib were investigated. Between April 2015 and June 2018, 85 patients with mCRC with FLT3 amplification were observed. There were no differences in baseline characteristics between patients with or without FLT3 amplification. The frequency of RAS or other gene co‐alterations was inversely correlated with the copy number status. Median survival time in patients with FLT3 amplification was significantly shorter compared with those with non‐FLT3 amplification. Further investigations of FLT3 amplification as a potential treatment target in mCRC are warranted. High FLT3 amplification may function not only as a prognostic factor but a promising treatment target in metastatic colorectal cancer. |
Databáze: | OpenAIRE |
Externí odkaz: |